Liana Fraenkel1,2, Zhenglin Wei3, Christine Ramsey4,5, Carole Wiedmeyer6, Kaleb Michaud7,8, Tuhina Neogi9, W Benjamin Nowell6, Shilpa Venkatachalam6, David A Broniatowski3. 1. Department of Medicine, Section of Rheumatology, Yale University School of Medicine, New Haven, Connecticut, United States of America. 2. Department of Medicine, Section of Rheumatology, Berkshire Health Systems, Pittsfield, Massachusetts, United States of America. 3. Department of Engineering Management and Systems Engineering, The George Washington University, Washington, DC, United States of America. 4. Mental Illness Research Education and Clinical Center, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, United States of America. 5. Yale Center for Medical Informatics, Yale School of Medicine, New Haven, CT, United States of America. 6. Patient-Centered Research, Global Heathy Living Foundation, Upper Nyack, NY, United States of America. 7. Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, United States of America. 8. Forward, The National Databank for Rheumatic Diseases, Wichita, KS, United States of America. 9. Department of Medicine, Section of Rheumatology, Boston University School of Medicine, Boston, MA, United States of America.
Abstract
OBJECTIVES: A measure that encompasses both benefits and harms at the individual patient level may facilitate comparisons between treatment options and improve shared decision-making. The objective of this study was to develop a patient reported measure to capture overall experience (including both benefits and harms) of treatment using rheumatoid arthritis (RA) as a case example. METHODS: Hierarchies for treatment benefits are known. Therefore, we developed a hierarchy of adverse events (AEs) using a series of trajectory mapping and paired comparison surveys. We subsequently used these data to construct a paired comparison survey, asking patients to compare options including both a specified level of benefit and an AE. These data were used to generate a hierarchy of overall experience on treatment. RESULTS: 782 participants completed a series of three surveys. The trajectory mapping procedure and a paired comparison survey led to the generation of a hierarchy of AEs with nine levels ranging from No AEs to irreversible serious complications. In a third survey, in which AEs were paired with benefits, participants' ratings generated a 6-level hierarchy of overall experiences ranging from Major improvement + No, mild or manageable AEs (Level 1) to No improvement + Irreversible AEs (Level 6). CONCLUSIONS: Using a trajectory mapping approach, we developed a patient reported measure representing the distribution of patients' overall experiences on treatment. The intent of this measure is to enable patients and their physicians to compare the percentage of patients experiencing each level of outcome, from most to least desirable, across treatments.
OBJECTIVES: A measure that encompasses both benefits and harms at the individual patient level may facilitate comparisons between treatment options and improve shared decision-making. The objective of this study was to develop a patient reported measure to capture overall experience (including both benefits and harms) of treatment using rheumatoid arthritis (RA) as a case example. METHODS: Hierarchies for treatment benefits are known. Therefore, we developed a hierarchy of adverse events (AEs) using a series of trajectory mapping and paired comparison surveys. We subsequently used these data to construct a paired comparison survey, asking patients to compare options including both a specified level of benefit and an AE. These data were used to generate a hierarchy of overall experience on treatment. RESULTS: 782 participants completed a series of three surveys. The trajectory mapping procedure and a paired comparison survey led to the generation of a hierarchy of AEs with nine levels ranging from No AEs to irreversible serious complications. In a third survey, in which AEs were paired with benefits, participants' ratings generated a 6-level hierarchy of overall experiences ranging from Major improvement + No, mild or manageable AEs (Level 1) to No improvement + Irreversible AEs (Level 6). CONCLUSIONS: Using a trajectory mapping approach, we developed a patient reported measure representing the distribution of patients' overall experiences on treatment. The intent of this measure is to enable patients and their physicians to compare the percentage of patients experiencing each level of outcome, from most to least desirable, across treatments.
Authors: Amylou C Dueck; Tito R Mendoza; Sandra A Mitchell; Bryce B Reeve; Kathleen M Castro; Lauren J Rogak; Thomas M Atkinson; Antonia V Bennett; Andrea M Denicoff; Ann M O'Mara; Yuelin Li; Steven B Clauser; Donna M Bryant; James D Bearden; Theresa A Gillis; Jay K Harness; Robert D Siegel; Diane B Paul; Charles S Cleeland; Deborah Schrag; Jeff A Sloan; Amy P Abernethy; Deborah W Bruner; Lori M Minasian; Ethan Basch Journal: JAMA Oncol Date: 2015-11 Impact factor: 31.777
Authors: Edward Keystone; Mark C Genovese; Lars Klareskog; Elizabeth C Hsia; Stephen Hall; Pedro C Miranda; Jacek Pazdur; Sang-Cheol Bae; William Palmer; Stephen Xu; Mahboob U Rahman Journal: Ann Rheum Dis Date: 2010-05-05 Impact factor: 19.103
Authors: Thomas M Atkinson; Jennifer L Hay; Amylou C Dueck; Sandra A Mitchell; Tito R Mendoza; Lauren J Rogak; Lori M Minasian; Ethan Basch Journal: J Pain Symptom Manage Date: 2017-11-10 Impact factor: 3.612
Authors: Scott R Evans; Daniel Rubin; Dean Follmann; Gene Pennello; W Charles Huskins; John H Powers; David Schoenfeld; Christy Chuang-Stein; Sara E Cosgrove; Vance G Fowler; Ebbing Lautenbach; Henry F Chambers Journal: Clin Infect Dis Date: 2015-06-25 Impact factor: 9.079
Authors: Daniel E Singer; Yuchiao Chang; Margaret C Fang; Leila H Borowsky; Niela K Pomernacki; Natalia Udaltsova; Alan S Go Journal: Ann Intern Med Date: 2009-09-01 Impact factor: 25.391
Authors: D T Felson; J J Anderson; M Boers; C Bombardier; M Chernoff; B Fried; D Furst; C Goldsmith; S Kieszak; R Lightfoot Journal: Arthritis Rheum Date: 1993-06
Authors: W Benjamin Nowell; Peter A Merkel; Robert N McBurney; Kalen Young; Shilpa Venkatachalam; Dianne G Shaw; Angela Dobes; Emily Cerciello; Laura Kolaczkowski; Jeffrey R Curtis; Michael D Kappelman Journal: Patient Date: 2021-04-27 Impact factor: 3.883